Camber Capital Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Camber Capital Management’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-649,097	Closed	-$5.65M	–	45
2016 Q2	$5.65M	Hold	649,097	–	–	0.27%	42
2016 Q1	$3.42M	Hold	649,097	–	–	0.2%	43
2015 Q4	$5.04M	Sell	649,097 -75,000	-10%	-$576K	0.33%	38
2015 Q3	$5.7M	Sell	724,097 -293,800	-29%	-$2.72M	0.49%	37
2015 Q2	$9.22M	Sell	1,017,897 -464,765	-31%	-$4.69M	0.63%	36
2015 Q1	$19.2M	Sell	1,482,662 -265,438	-15%	-$3.47M	1.37%	22
2014 Q4	$23.8M	Buy	1,748,100 +840,000	+93%	+$9.39M	1.58%	26
2014 Q3	$8.15M	Hold	908,100	–	–	0.77%	30
2014 Q2	$12.3M	Hold	908,100	–	–	0.81%	32
2014 Q1	$9.03M	Sell	908,100 -41,900	-4%	-$521K	0.71%	33
2013 Q4	$12.6M	Hold	950,000	–	–	1.12%	27
2013 Q3	$11.5M	Hold	950,000	–	–	1.21%	24
2013 Q2	$9.82M	Buy	+950,000	New	+$13.1M	1.01%	28

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Camber Capital Management's GNMK Position: Q3 2016 in Review

Camber Capital Management sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2016, closing a stake of 649,097 shares — an estimated $5.65M sold.

Camber Capital Management first reported a position in GNMK in Q2 2013 and held it in 13 quarters. The position peaked at $23.8M in Q4 2014. 91 funds tracked by Wall St. Rank hold GNMK as of Q3 2016.

Camber Capital Management reported no remaining GenMark Diagnostics, Inc position as of Q3 2016 after selling out during the quarter.
Camber Capital Management sold 649,097 GenMark Diagnostics, Inc shares in Q3 2016, an estimated $5.65M.
Camber Capital Management first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 13 quarters.
Camber Capital Management's GenMark Diagnostics, Inc position peaked at $23.8M in Q4 2014.
91 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2016.

Based on Camber Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.